CIA BRASILEIRA DE DIS- ADR (CBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CBD - US20440T3005 - ADR
0.445 USD
-0.01 (-3.05%)
0.4357 USD
-0.01 (-2.09%)
We assign a fundamental rating of 2 out of 10 to CBD. CBD was compared to 38 industry peers in the Consumer Staples Distribution & Retail industry. CBD has a bad profitability rating. Also its financial health evaluation is rather negative. CBD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CBD has reported negative net income.
In the past year CBD had a positive cash flow from operations.
In multiple years CBD reported negative net income over the last 5 years.
Of the past 5 years CBD 4 years had a positive operating cash flow.
1.2 Ratios
CBD's Return On Assets of -10.30% is on the low side compared to the rest of the industry. CBD is outperformed by 78.05% of its industry peers.
CBD has a Return On Equity of -48.12%. This is amonst the worse of the industry: CBD underperforms 80.49% of its industry peers.
CBD's Return On Invested Capital of 0.48% is on the low side compared to the rest of the industry. CBD is outperformed by 70.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROIC | 0.48% |
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 0.50%, CBD is not doing good in the industry: 68.29% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of CBD has declined.
With a decent Gross Margin value of 25.02%, CBD is doing good in the industry, outperforming 63.41% of the companies in the same industry.
In the last couple of years the Gross Margin of CBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% |
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CBD is destroying value.
CBD has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for CBD is higher compared to a year ago.
2.2 Solvency
CBD has an Altman-Z score of 1.07. This is a bad value and indicates that CBD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.07, CBD is doing worse than 73.17% of the companies in the same industry.
A Debt/Equity ratio of 1.72 is on the high side and indicates that CBD has dependencies on debt financing.
CBD has a worse Debt to Equity ratio (1.72) than 82.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.07 |
ROIC/WACC0.09
WACC5.48%
2.3 Liquidity
CBD has a Current Ratio of 1.21. This is a normal value and indicates that CBD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.21, CBD is in line with its industry, outperforming 51.22% of the companies in the same industry.
CBD has a Quick Ratio of 1.21. This is a bad value and indicates that CBD is not financially healthy enough and could expect problems in meeting its short term obligations.
CBD has a better Quick ratio (0.89) than 70.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
CBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1171.43%.
The Revenue for CBD has decreased by -59.86% in the past year. This is quite bad
The Revenue for CBD have been decreasing by -17.17% on average. This is quite bad
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
3.2 Future
The Earnings Per Share is expected to grow by 24.83% on average over the next years. This is a very strong growth
CBD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.97% yearly.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
CBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CBD is cheaper than 85.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 5 |
4.3 Compensation for Growth
CBD's earnings are expected to grow with 24.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 13.41%, CBD is a good candidate for dividend investing.
In the last 3 months the price of CBD has falen by -47.63%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
CBD's Dividend Yield is rather good when compared to the industry average which is at 0.77. CBD pays more dividend than 100.00% of the companies in the same industry.
CBD's Dividend Yield is rather good when compared to the S&P500 average which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
5.2 History
The dividend of CBD decreases each year by -24.04%.
CBD has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The earnings of CBD are negative and hence is the payout ratio. CBD will probably not be able to sustain this dividend level.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
0.445
-0.01 (-3.05%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)
Earnings (Next)
Inst Owners0.12%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap218.06M
Revenue(TTM)19.25B
Net Income(TTM)-2.27B
Analysts50
Price Target1.53 (243.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 13.41% |
Yearly Dividend0.41
Dividend Growth(5Y)-24.04%
DP-4.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-273.86%
Min EPS beat(2)-455.83%
Max EPS beat(2)-91.89%
EPS beat(4)0
Avg EPS beat(4)-228.76%
Min EPS beat(4)-455.83%
Max EPS beat(4)-25.58%
EPS beat(8)0
Avg EPS beat(8)-362.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-4.34%
Max Revenue beat(2)-3.47%
Revenue beat(4)0
Avg Revenue beat(4)-27.12%
Min Revenue beat(4)-59.79%
Max Revenue beat(4)-3.47%
Revenue beat(8)2
Avg Revenue beat(8)-9.38%
Revenue beat(12)3
Avg Revenue beat(12)-9.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.66%
PT rev (3m)-10.73%
EPS NQ rev (1m)54.81%
EPS NQ rev (3m)58.85%
EPS NY rev (1m)49.53%
EPS NY rev (3m)46.14%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.06 | ||
| P/FCF | N/A | ||
| P/OCF | 1.99 | ||
| P/B | 0.24 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | 5 |
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.22
OCFY50.28%
SpS7.65
BVpS1.88
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.3% | ||
| ROE | -48.12% | ||
| ROCE | 0.61% | ||
| ROIC | 0.48% | ||
| ROICexc | 0.63% | ||
| ROICexgc | 0.76% | ||
| OM | 0.5% | ||
| PM (TTM) | N/A | ||
| GM | 25.02% | ||
| FCFM | N/A |
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-58.82%
ROICexgc growth 5Y-42.48%
ROICexc growth 3Y-57.55%
ROICexc growth 5Y-42.78%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
F-Score2
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.72 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.59 | ||
| Cap/Depr | 103.08% | ||
| Cap/Sales | 6.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 45.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.07 |
F-Score2
WACC5.48%
ROIC/WACC0.09
Cap/Depr(3y)82.81%
Cap/Depr(5y)104.8%
Cap/Sales(3y)7.75%
Cap/Sales(5y)7.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
EBIT growth 1Y-87.1%
EBIT growth 3Y-67.17%
EBIT growth 5Y-48.29%
EBIT Next Year586.28%
EBIT Next 3Y102.85%
EBIT Next 5Y76.66%
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y360.65%
OCF growth 3Y-50.85%
OCF growth 5Y-33.31%
CIA BRASILEIRA DE DIS- ADR / CBD FAQ
Can you provide the ChartMill fundamental rating for CIA BRASILEIRA DE DIS- ADR?
ChartMill assigns a fundamental rating of 2 / 10 to CBD.
What is the valuation status for CBD stock?
ChartMill assigns a valuation rating of 1 / 10 to CIA BRASILEIRA DE DIS- ADR (CBD). This can be considered as Overvalued.
Can you provide the profitability details for CIA BRASILEIRA DE DIS- ADR?
CIA BRASILEIRA DE DIS- ADR (CBD) has a profitability rating of 2 / 10.
Can you provide the financial health for CBD stock?
The financial health rating of CIA BRASILEIRA DE DIS- ADR (CBD) is 1 / 10.